DSIP
Also known as Delta Sleep-Inducing Peptide
Studied for: sleep architecture
DSIP is a nonapeptide first identified for its association with delta-wave sleep. Research examines its relationship with sleep architecture and with stress-hormone regulation.
Last reviewed September 26, 2026
How it is thought to work
Research investigates DSIP for influence on the slow-wave phase of sleep and for interaction with corticotropin-releasing signaling tied to the stress axis.
- Slow-Wave SleepStudied for association with delta-wave activity, the deepest, most restorative phase of the sleep cycle.
- Stress AxisExplored for interaction with the hormonal cascade that governs the stress response.
- Route studied
- Subcutaneous
- Research status
- Early clinical
DSIP has been characterized in laboratory and animal work and examined in small human studies, including a 1981 clinical trial on disturbed human sleep, but it has not progressed to large late-stage trials.
Research
What the research covers
What research examines
- Delta-wave (slow-wave) sleep activity
- Sleep architecture in disturbed human sleep
- Interaction with corticotropin-releasing stress-axis signaling
- Stress-hormone regulation
- Gastrointestinal absorption and gut immunoreactivity in animal models
Reported effects in studies
- Human safety data are limited
- Adverse events are not summarized in the cited studies
- Its mechanism of action remains incompletely resolved, per published reviews
Studied range
What research protocols have used
Research protocols have used 100–500 mcg per administration, once daily (pre-sleep), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- EpithalonEpithalon is a synthetic tetrapeptide studied for its potential role in cellular longevity and biological-rhythm pathways. Research explores its relationship with telomere biology and pineal signaling.Read profile$39
- IpamorelinIpamorelin is a selective growth-hormone secretagogue. Research examines it specifically for its selectivity, releasing growth hormone with minimal effect on cortisol or prolactin.Read profile$79
Studies
Cited research
- The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide.
Pflugers Archiv : European journal of physiology · 1978 · PMID 568769
- The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.
Experientia · 1981 · Clinical trial · PMID 7028502
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
Journal of neurochemistry · 2006 · Review · PMID 16539679
- Delta-sleep-inducing peptide (DSIP): an update.
Peptides · 1986 · Review · PMID 3550726
- Delta-sleep-inducing peptide (DSIP): a review.
Neuroscience and biobehavioral reviews · 1984 · Review · PMID 6145137
FAQ
Questions about DSIP
DSIP, or Delta Sleep-Inducing Peptide, is a nonapeptide, a chain of nine amino acids, first identified for its association with delta-wave sleep. Its amino-acid sequence and synthesis were described in 1978. Research has since examined its relationship with sleep architecture and with the regulation of stress hormones. Reviews spanning several decades have described it as a compound of continuing scientific interest whose biological role is still not fully resolved.
Research has investigated DSIP for an influence on the slow-wave phase of sleep, the deepest stage of the sleep cycle, which is marked by delta-wave activity on EEG. It has also been explored for interaction with corticotropin-releasing signaling, part of the hormonal cascade governing the stress response. A 2006 review described DSIP as a still unresolved riddle, reflecting that a precise receptor and mechanism have not been firmly established.
Studies have examined DSIP in relation to delta-wave sleep, sleep architecture, and stress-axis signaling. A small 1981 clinical trial looked at the influence of synthetic DSIP on disturbed human sleep. Animal work has studied the absorption of DSIP-like material from the gastrointestinal tract of neonatal rats, and other research has described DSIP-like immunoreactivity in gut tissue alongside known peptide hormones. Materials research has also explored entrapping DSIP in porous matrices.
Human safety data for DSIP are limited. The available human research consists of small studies, and adverse events are not summarized in the cited studies. Published reviews emphasize that its mechanism remains incompletely understood, which limits firm conclusions about its safety profile. DSIP is supplied by CoreX for laboratory research use only, and its safety has not been established through large controlled trials.
Research protocols have used 100 to 500 mcg per administration, once daily before sleep, in 8-week blocks followed by 4 weeks off, with subcutaneous administration described as the route. These figures reflect what research protocols have reported and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. DSIP is sold for research use only.
Ask about DSIP
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.